- Research article
- Open Access
Differentiation of human multipotent dermal fibroblasts into islet-like cell clusters
- Dan Bi1Email author,
- Fu Guo Chen1Email author,
- Wen Jie Zhang†1,
- Guang Dong Zhou1,
- Lei Cui1,
- Wei Liu1 and
- Yilin Cao†1
© Bi et al; licensee BioMed Central Ltd. 2010
- Received: 19 August 2009
- Accepted: 25 June 2010
- Published: 25 June 2010
We have previously obtained a clonal population of cells from human foreskin that is able to differentiate into mesodermal, ectodermal and endodermal progenies. It is of great interest to know whether these cells could be further differentiated into functional insulin-producing cells.
Sixty-one single-cell-derived dermal fibroblast clones were established from human foreskin by limiting dilution culture. Of these, two clones could be differentiated into neuron-, adipocyte- or hepatocyte-like cells under certain culture conditions. In addition, those two clones were able to differentiate into islet-like clusters under pancreatic induction. Insulin, glucagon and somatostatin were detectable at the mRNA and protein levels after induction. Moreover, the islet-like clusters could release insulin in response to glucose in vitro.
This is the first study to demonstrate that dermal fibroblasts can differentiate into insulin-producing cells without genetic manipulation. This may offer a safer cell source for future stem cell-based therapies.
- Dermal Fibroblast
- Adipogenic Differentiation
- Glucose Stimulation
- Pancreatic Differentiation
- Hepatogenic Differentiation
Type 1 diabetes is an autoimmune disease that results in the destruction of insulin-producing beta cells of the pancreas . Increasing evidence suggests that islet transplantation is a promising therapy for type 1 diabetes. However, the limited supply of donors for pancreatic islets severely limits this approach. The use of stem cells to produce a new population of functional beta cells may offer an alternative approach. Embryonic and adult stem cells, including mesenchymal stem cells, hepatic oval cells, adult pancreatic stem cells, and pancreatic-ducts stem cells, are able to differentiate into insulin-secreting cells in vitro and correct hyperglycemia in diabetic animal models [2–8].
Recent studies have demonstrated that dermal fibroblasts can be reprogrammed into embryonic stem cell-like cells called induced pluripotent stem (iPS) cells by introducing several stem cell-associated genes [9, 10]. Tateishi et al. showed that dermal fibroblast-derived iPS cells could also generate insulin secreting islet-like cells , suggesting that iPS cells might be a potential cell source for therapy. However, the genetic manipulation involved could be problematic for future clinical applications.
In our previous study, we isolated, expanded and characterized one clonal population from dermal fibroblasts, which is able to differentiate into mesodermal, ectodermal and endodermal progenies in vitro . It is of great interest to know whether these cells can be further differentiated into functional insulin-producing cells. Thus, the aim of this study was to establish clones from the human dermis with greater multipotency, and to investigate their potential to differentiate into pancreatic cells.
Differentiation potential of single-cell derived dermal fibroblasts
In vitro differentiation of MDFs into islet-like clusters
Release of insulin in response to glucose stimulation
Numerous studies have demonstrated the presence of stem cells in the adult dermis [14, 15]. Our previous study revealed that dermal fibroblasts are a heterogeneous population that contains cells with variable differentiation potential . In the present study, we confirmed that a small population of cells from human foreskin is multipotent. These cells could be differentiated into neuron-, adipocyte- and hepatocyte-like cells in the presence of certain factors. More importantly, these cells could differentiate into islet-like cells capable of expressing insulin, glucagon and somatostatin after pancreatic induction. In addition, the islet-like clusters could release insulin in response to glucose in vitro.
Pancreatic differentiation of MDFs has been demonstrated by the expression of pancreatic genes at the mRNA (Figure 4) level. Although, immunoreactivity of insulin was observed in the cell clusters after induction (Figure 2C), it can not rule out the possibility that the insulin is trapped in clusters, since the media contains FBS/insulin . By anti-C-peptide immunostaining, we confirmed that induced cells do express insulin (Figure 2D, E). Unfortunately, the functional assay showed that the islet-like cells released insulin in response to glucose stimulation with limited ability (Figure 5). The low insulin secretory capacity may be due to the loss of stem cell properties during MDF expansion. We have found that cells after 30 cell-doublings completely lose their multipotency (data not shown). Thus, the cells investigated in this study (approximately 25 cell-doublings) were close to their capacity. Optimal cell expansion conditions are worth to be investigated to improve the pancreatic differentiation ability. Meanwhile, the in vivo function of insulin-producing cells is under investigation in diabetic animals.
Vimentin is the marker of mensenchymal cells. The MDFs express vimentin even after pancreatic induction (Figure 4). Although there have been reports of epithelial-to-mesenchymal transition (EMT) of pancreatic islet cells and differentiation of such cells back to insulin-producing cells [16–18], it is hard to believe that skin epithelial cells undergo EMT to differentiate into pancreatic cells. Guo et al. reported that skin-derived precursors (SKPs) from mouse, which express nestin but not vimentin, could also be differentiated into insulin producing cells, indicating that EMT is not likely the mechanisms for differentiation of skin cells to pancreatic cells. As we discussed previously, the relationship between SKPs and the multipotent dermal fibroblasts in our study is still unclear . Nevertheless, it supports our findings that skin contains multipotent cells that could be differentiated into islet-like cells.
The finding that MDFs could give rise to cells of three germ layers is surprising. Interestingly, similar types of multipotent cells have been isolated from other adult tissues, such as spermatogonial stem cells in the adult testis  and very small embryonic-like (VSEL) stem cells in the bone marrow . Kucia et al. speculated that the multipotent stem cells in adult tissues might be derived from early embryonic cells that reside in different tissues during developmental process and are maintained to the adult stage . It could be speculated that those MDFs might be derived from residual undifferentiated cells in the dermis. To further localize these cells in the dermis and to enrich them from the pooled population, the characteristics unique to these cells are under investigation.
Recent studies have demonstrated that the iPS cells derived from reprogramming of dermal fibroblasts are multipotent and could generate insulin secreting islet-like cells . The relationship between MDFs and iPS cells should also be investigated. Kim et al. demonstrated that the induction of iPS from stem cells seems to be easier than that from differentiated cells . One possibility is that the reprogramming process might mainly occur in MDFs rather than in the differentiated dermal fibroblasts. Thus, only MDFs could selectively expand in culture. Moreover, the number of reprogramming factors could be reduced when using MDFs as a target. Further studies are needed to answer these questions.
In summary, this is the first study to demonstrate that multipotent dermal fibroblasts could be differentiated into islet-like cells without genetic manipulation. This approach might offer a safer cell source for future stem cell-based therapies.
Derivation of single-cell derived clones from dermis
Single-cell derived clones were established according to the method described by Chen et al. . Briefly, fresh human foreskin specimens were obtained from 14 donors aged from 6 to 12 years who underwent a routine circumcision procedure at Shanghai Children's Hospital with informed consent. The study was performed with approval from the local ethics committee (Shanghai Jiao Tong University School of Medicine, China). The single-cell suspension was achieved after enzyme digestion and filtration. The cells were then suspended in high-glucose DMEM (DMEM-HG; Invitrogen Corporation, Carlsbad, CA, USA), supplemented with 10% FBS (HyClone, Logan, UT), 300 μg/m1 L-glutamine, 50 μg/ml vitamin C, 100 U/ml penicillin and 100 μg/ml streptomycin (all from Sigma, St Louis, MO, USA). The cells were then seeded in 96-well tissue culture plates (Falcon, Franklin Lakes, NT) at a concentration of 2 cells/well (200 μl/well, five plates/donor). After 24 h, the plates were scored under the microscope. Wells containing only one cell were marked for further analysis. The cells were kept in the original culture medium at 37°C with 5% CO2. After 2-3 weeks, the single-cell-derived clones were harvested and transferred to 24-well and six-well tissue culture plates (Falcon) for expansion. In total, 61 clones were established, and their differentiation potential was analyzed.
Multilineage differentiation of single-cell derived clones
Single-cell-derived clones were analyzed for their capacity to differentiate into adipocytes, neuron and hepatocytes. Each experiment was repeated at least three times for cells from each clone.
Adipogenic differentiation was performed as previously described . Briefly, cells were seeded at 1 × 103 cells/cm2 in adipogenic medium for 3 weeks. Cells cultured in the regular culture medium were used as a control. The medium was changed every 3 days. Cells were stained with Oil Red O reagent (Sigma) for 5 minutes after induction.
Neurogenic differentiation was performed as previously described . Briefly, cells were seeded at 1 × 103 cells/cm2 on fibronectin-coated dishes, incubated with sequential changes in neurogenic medium for up to 10 days. Cells maintained in regular culture medium were used as a control.
Hepatogenic differentiation was performed as described by Schwartz et al. . Cells were seeded at 4 × 103 cells/cm2 on fibronectin-coated dishes, pre-induced for 10 h followed by culturing with hepatogenic medium for up to 3 weeks. The medium was changed every 2 days. Cells maintained within the regular culture medium were used as a control.
Pancreatic differentiation of multipotent dermal fibroblasts in vitro
To induce the multipotent dermal fibroblasts (MDFs) to undergo pancreatic endocrine cell differentiation, the cells were treated by sequential specification, commitment and differentiation with factors known to promote the expression of a beta cell-like phenotype, as previously described [2, 25–27]. Briefly, cells were plated at a density of 10,000 cells/cm2 in the presence of DMEM-HG, 20% FBS for 24 hours. On the next day, medium containing DMEM-HG, 20% FBS and 10 ng/ml b-FGF (#233-FB-025; R&D Systems, Minneapolis, MN) was added for another 24 hours. Endodermal specification was then induced by exposure to medium containing DMEM-HG, 1% DMSO (#D4540; Sigma), 100 mM butylated hydroxyanisole (BHA, #B1253; Sigma), and 10 nM exendin-4 (#E7144; Sigma) for 24 hours. Cells were washed three times, and endodermal commitment was induced by exposure to medium containing RPMI 1640 (#12633-012; Invitrogen), 11.1 mM glucose, 10% FBS, 1.0 mM sodium pyruvate, 10 mM Hepes (#H3375; Sigma),20 ng/ml b-FGF and 20 ng/ml EGF (#236-EG-200; R&D Systems), and 10 nM exendin-4 for 4 days. Islet-like differentiation was subsequently induced by exposing the cells to medium composed of RPMI 1640, 2.5 mM glucose, 10 mM Hepes, 10 mM nicotinamide (#N0636; Sigma), 100 pM HGF (#H1404; R&D Systems), 10 nM exendin-4, and 2.0 nM activin-A (#A4941; Sigma) for 5-7 days.
To stain intracellular proteins, the cells were fixed in 4% cold paraformaldehyde (Sigma) in phosphate-buffered saline (PBS) for 15 minutes on chamber slides, and permeabilized with 0.25% Triton X-100 (Sigma) in PBS for 10 minutes. The blocking and diluent solutions comprised PBS, 1% BSA and 1% serum (Sigma) from the species in which the secondary antibody was raised. The fixed cells were blocked for 30 minutes, incubated sequentially with the primary antibodies diluted in PBS at 4°C overnight, followed by incubation with secondary antibodies. Cells exposed to isotypic antibodies were used as controls. Nuclei were counterstained by DAPI (4', 6'-diamidino-2-phenylindole, Invitrogen). The primary antibodies, including anti-neurotensin receptor 3 (NTR-3, 1:100), anti-growth associated protein-43 (GAP-43, 1:100), anti-neurofilament (NF-M, 1:100), anti-hepatic nuclear factor 3 beta (HNF-3β, 1:100), anti-albumin (ALB, 1:100), anti-insulin (1:100), anti-C-peptide (1:100), anti-glucagon (1:100) and anti-somatostatin (SOM, 1:100) were purchased from Santa Cruz Biotechnology. Secondary antibodies, including anti-goat IgG (H+L), anti-rabbit IgG (H+L), anti-mouse IgG (H+L) labeled with Alexa Fluor 488 or Alexa Fluor 546 (1:1000 Molecular Probes, Invitrogen), were used according to the manufacturer's recommendations.
Primers used in RT-PCR analysis
Number of cycles
Annealing temperature (°C)
Sense: 5'-GCCTTTGTGAACCAACACCTG -3'
Antisense: 5'-GTTGCAGTAGTTCTCCAGCTG -3'
Sense: 5'-ATCTGGACTCCAGGCGTGCC -3'
Antisense: 5'-AGCAATGAATTCCTTGGCAG -3'
Sense: 5'-CAACAAACAAAACGCAAAAC -3'
Antisense: 5'-AAGTCAAACACAATCCCGA -3'
Sense: 5'-GTCCTGGAGGAGCCCAAC -3'
Antisense: 5'-GCAGTCCTGCTCAGGCTC -3'
Sense: 5'-GAAAGCCCTCTGACTGAT -3'
Antisense: 5'-AAACTGGCGTGCCTCTAA -3'
Antisense: 5'-TCAGTGCCAACTCGCTCT TAGG-3'
Glucose-regulated insulin secretion
To determine whether cells could respond to glucose in vitro, the differentiated cells were pre-incubated for 4 hours at 37°C in Krebs-Ringer bicarbonate Hepes (KRBH) buffer containing 118 mM sodium chloride, 4.7 mM potassium chloride, 1.1 mM potassium dihydrogen phosphate, 25 mM sodium hydrogen carbonate, 3.4 mM calcium chloride, 2.5 mM magnesium sulfate, 10 mM Hepes and 2 mg/ml bovine serum albumin (BSA). For high-glucose-induced insulin release, cells were incubated in KRBH buffer supplemented with different concentrations of glucose (0-10 mM) together with 10 μM tolbutamide (Sigma) for 2 hours at 37°C. The concentration of insulin secreted into the culture media was measured using an ultra-sensitive human insulin enzyme-linked immunosorbent assay (ELISA) kit (Diagnostic Systems Laboratories, Webster, TX, USA). Cells were collected and total protein was determined using the DC protein assay system (Bio-Rad, Hercules, CA, USA). The data are presented as secreted insulin/total protein (ng/mg). Clone 27 and 45 were measured separately and each clone was repeated three times.
Each experiment was repeated at least three times. All data are presented as means ± standard deviation. The data of insulin release after glucose stimulation were subjected to one-way analysis of variance (ANOVA) using the SPSS version 13.0, and the Student Newman-Keuls test was used for multiple comparisons. P values less than 0.05 are interpreted as significant.
This work was supported by the Major State Basic Research Development Program of China (2005CB522700), National Basic Research Program of China (30800231), Shanghai Pu Jiang foundation (to Zhang WJ), and Shanghai Shu Guang foundation (to Zhang WJ). The authors also appreciate the technical support from Deli Liu, Demin Ying, Lijuan Zong and Juanjuan Wu.
- Gepts W: Islet morphology in type I diabetes. Behring Inst Mitt. 1984, 39-41. 75Google Scholar
- Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R, McKay R: Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science. 2001, 292 (5520): 1389-1394. 10.1126/science.1058866.View ArticlePubMedGoogle Scholar
- Karnieli O, Izhar-Prato Y, Bulvik S, Efrat S: Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation. Stem Cells. 2007, 25 (11): 2837-2844. 10.1634/stemcells.2007-0164.View ArticlePubMedGoogle Scholar
- Zalzman M, Gupta S, Giri RK, Berkovich I, Sappal BS, Karnieli O, Zern MA, Fleischer N, Efrat S: Reversal of hyperglycemia in mice by using human expandable insulin-producing cells differentiated from fetal liver progenitor cells. Proc Natl Acad Sci USA. 2003, 100 (12): 7253-7258. 10.1073/pnas.1136854100.PubMed CentralView ArticlePubMedGoogle Scholar
- Kojima H, Fujimiya M, Matsumura K, Younan P, Imaeda H, Maeda M, Chan L: NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat Med. 2003, 9 (5): 596-603. 10.1038/nm867.View ArticlePubMedGoogle Scholar
- Ramiya VK, Maraist M, Arfors KE, Schatz DA, Peck AB, Cornelius JG: Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nat Med. 2000, 6 (3): 278-282. 10.1038/73128.View ArticlePubMedGoogle Scholar
- Bonner-Weir S, Taneja M, Weir GC, Tatarkiewicz K, Song KH, Sharma A, O'Neil JJ: In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci USA. 2000, 97 (14): 7999-8004. 10.1073/pnas.97.14.7999.PubMed CentralView ArticlePubMedGoogle Scholar
- Chandra V, G S, Phadnis S, Nair PD, Bhonde RR: Generation of Pancreatic Hormone-Expressing Islet-Like Cell Aggregates from Murine Adipose Tissue-Derived Stem Cells. Stem Cells. 2009, 27 (8): 1941-1953. 10.1002/stem.117.View ArticlePubMedGoogle Scholar
- Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007, 131 (5): 861-872. 10.1016/j.cell.2007.11.019.View ArticlePubMedGoogle Scholar
- Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ: Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008, 451 (7175): 141-146. 10.1038/nature06534.View ArticlePubMedGoogle Scholar
- Tateishi K, He J, Taranova O, Liang G, D'Alessio AC, Zhang Y: Generation of insulin-secreting islet-like clusters from human skin fibroblasts. J Biol Chem. 2008, 283 (46): 31601-31607. 10.1074/jbc.M806597200.View ArticlePubMedGoogle Scholar
- Chen FG, Zhang WJ, Bi D, Liu W, Wei X, Chen FF, Zhu L, Cui L, Cao Y: Clonal analysis of nestin(-) vimentin(+) multipotent fibroblasts isolated from human dermis. J Cell Sci. 2007, 120 (Pt 16): 2875-2883. 10.1242/jcs.03478.View ArticlePubMedGoogle Scholar
- Rajagopal J, Anderson WJ, Kume S, Martinez OI, Melton DA: Insulin staining of ES cell progeny from insulin uptake. Science. 2003, 299 (5605): 363-PubMedGoogle Scholar
- Bartsch G, Yoo JJ, De Coppi P, Siddiqui MM, Schuch G, Pohl HG, Fuhr J, Perin L, Soker S, Atala A: Propagation, expansion, and multilineage differentiation of human somatic stem cells from dermal progenitors. Stem Cells Dev. 2005, 14 (3): 337-348. 10.1089/scd.2005.14.337.View ArticlePubMedGoogle Scholar
- Toma JG, McKenzie IA, Bagli D, Miller FD: Isolation and characterization of multipotent skin-derived precursors from human skin. Stem Cells. 2005, 23 (6): 727-737. 10.1634/stemcells.2004-0134.View ArticlePubMedGoogle Scholar
- Joglekar MV, Patil D, Joglekar VM, Rao GV, Reddy DN, Sasikala M, Shouche Y, Hardikar AA: The miR-30 Family microRNAs Confer Epithelial Phenotype to Human Pancreatic Cells. Islets. 2009, 49 (1): 137-147. 10.4161/isl.1.2.9578.View ArticleGoogle Scholar
- Efrat S: In vitro expansion of human beta cells. Diabetologia. 2008, 51 (7): 1338-1339. 10.1007/s00125-008-1024-x.View ArticlePubMedGoogle Scholar
- Gershengorn MC, Hardikar AA, Wei C, Geras-Raaka E, Marcus-Samuels B, Raaka BM: Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science. 2004, 306 (5705): 2261-2264. 10.1126/science.1101968.View ArticlePubMedGoogle Scholar
- Guo W, Miao C, Liu S, Qiu Z, Li J, Duan E: Efficient differentiation of insulin-producing cells from skin-derived stem cells. Cell Prolif. 2009, 42 (1): 49-62. 10.1111/j.1365-2184.2008.00573.x.View ArticlePubMedGoogle Scholar
- Kanatsu-Shinohara M, Inoue K, Lee J, Yoshimoto M, Ogonuki N, Miki H, Baba S, Kato T, Kazuki Y, Toyokuni S: Generation of pluripotent stem cells from neonatal mouse testis. Cell. 2004, 119 (7): 1001-1012. 10.1016/j.cell.2004.11.011.View ArticlePubMedGoogle Scholar
- Kucia M, Wysoczynski M, Ratajczak J, Ratajczak MZ: Identification of very small embryonic like (VSEL) stem cells in bone marrow. Cell Tissue Res. 2008, 331 (1): 125-134. 10.1007/s00441-007-0485-4.View ArticlePubMedGoogle Scholar
- Kim JB, Zaehres H, Wu G, Gentile L, Ko K, Sebastiano V, Arauzo-Bravo MJ, Ruau D, Han DW, Zenke M: Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature. 2008, 454 (7204): 646-650. 10.1038/nature07061.View ArticlePubMedGoogle Scholar
- D'Ippolito G, Diabira S, Howard GA, Menei P, Roos BA, Schiller PC: Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci. 2004, 117 (Pt 14): 2971-2981. 10.1242/jcs.01103.View ArticlePubMedGoogle Scholar
- Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, Lenvik T, Johnson S, Hu WS, Verfaillie CM: Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest. 2002, 109 (10): 1291-1302.PubMed CentralView ArticlePubMedGoogle Scholar
- Hunziker E, Stein M: Nestin-expressing cells in the pancreatic islets of Langerhans. Biochem Biophys Res Commun. 2000, 271 (1): 116-119. 10.1006/bbrc.2000.2611.View ArticlePubMedGoogle Scholar
- Movassat J, Beattie GM, Lopez AD, Hayek A: Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells. J Clin Endocrinol Metab. 2002, 87 (10): 4775-4781. 10.1210/jc.2002-020137.View ArticlePubMedGoogle Scholar
- Zulewski H, Abraham EJ, Gerlach MJ, Daniel PB, Moritz W, Muller B, Vallejo M, Thomas MK, Habener JF: Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes. 2001, 50 (3): 521-533. 10.2337/diabetes.50.3.521.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.